Cochlear (FRA:OC5) Other Long Term Assets: €155 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC5 Cochlear Ltd FRA:OC5
68 GF Score
Price €82.87
GF Value €187.21
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cochlear Other Long Term Assets?

Cochlear FRA:OC5 -2.62% 68 Other Long Term Assets is €155 Mil as of Jun. 2026. GuruFocus rates FRA:OC5 with a GF Score™ of 68/100 and a GF Value™ of €187.21 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Cochlear's other long-term assets for the quarter that ended in Jun. 2026 was €155 Mil.

Cochlear's quarterly other long-term assets declined from Jun. 2025 (€165 Mil) to Dec. 2025 (€109 Mil) but then increased from Dec. 2025 (€109 Mil) to Jun. 2026 (€155 Mil).

Cochlear's annual other long-term assets increased from Jun. 2024 (€149 Mil) to Jun. 2025 (€165 Mil) but then declined from Jun. 2025 (€165 Mil) to Jun. 2026 (€155 Mil).

Cochlear Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Cochlear's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Other Long Term Assets Chart

Cochlear Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.52 135.41 148.91 164.99 154.57

Cochlear Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.91 103.54 164.99 108.61 154.57
FRA:OC5
68GF Score
Cochlear Ltd FRA:OC5
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €155 Mil mean?
Cochlear (FRA:OC5) has a Other Long Term Assets of €155 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cochlear and its competitors.
Is Cochlear's Other Long Term Assets too high?
Cochlear's current Other Long Term Assets is €155 Mil. Overall, Cochlear has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Other Long Term Assets compare to ABT and SYK?
Cochlear's Other Long Term Assets of €155 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Devices & Instruments company?
A good Other Long Term Assets depends on the Medical Devices & Instruments industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cochlear and its competitors. Cochlear's current Other Long Term Assets is €155 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €187.21, compared to a current price of €82.87 — trading 55.7% below its estimated fair value. The current Other Long Term Assets is €155 Mil. Cochlear's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Cochlear (FRA:OC5), the current Other Long Term Assets is €155 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (FRA:OC5) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of €82.87 is trading 55.7% below its estimated GF Value™ of €187.21. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for FRA:OC5:

  • Other Long Term Assets: €155 Mil
  • GF Value™: €187.21 vs. price of €82.87 (55.7% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
68GF Score

Get the complete analysis for FRA:OC5

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.87
Price
€187.21
GF Value